Evaluation of Abdominal Wall Block With Liposomal Bupivacaine for Post-Operative Analgesia in Donor Nephrectomy
Status:
Completed
Trial end date:
2020-06-24
Target enrollment:
Participant gender:
Summary
A blinded randomized control trial in living kidney donors. The study group will receive a
liposomal bupivacaine Trans Quadratus Lumborum (TQL) block after the induction of general
anesthesia. The following study variables will be collected postoperatively following arrival
in the post-anesthesia care unit. Current and maximum intensity pain scores will be
documented by nurses in Electronic Health Record (EHR). Total opiate dose consumed every 24
hours will be collected from the EHR and pain diary after discharge. Patient satisfaction
will be evaluated using the Revised American Pain Society Patient Outcome Questionnaire
(APS-POQ-R) 24 hours' post-procedure. Incidence of nausea will be extracted from nursing
notes.